Articles tagged with Tuberculosis
Researchers at Hiroshima University discovered that pathogenic mycobacteria, such as Mycobacterium tuberculosis, attach to and multiply within human red blood cells. This interaction may play a role in the spread of lung diseases like tuberculosis.
A $4.76 million grant will support the evaluation of TB preventative treatment in six countries. The initiative aims to measure the impact of this life-saving treatment on reducing TB disease and mortality among people living with HIV.
The COVID-19 pandemic has led to a setback in global efforts to meet SDG targets for tackling tuberculosis. TB mortality plateaued in Europe between 2019 and 2020, likely due to disruptions in essential TB services. Researchers highlight the need for continued commitment and investments to prevent further progress being reversed.
Researchers discovered that mice infected with tuberculosis are resistant to developing COVID-19, suggesting a potential protective effect against the virus. The findings may explain why double infections of both diseases are rare in humans and contribute to the high rates of infection for each disease individually.
The Interdisciplinary NexGen TB Research Advancement Center will provide a world-class training program for the next generation of TB researchers, leveraging expertise and facilities across Texas Biomed and South Texas. The center aims to ensure diverse skills and real-world experience to effectively tackle this challenging disease.
Researchers develop novel therapeutic approach for treating tuberculosis using phosphatase inhibitors, offering potential benefits for TB research and basic biology exploration. The discovery provides a promising alternative to traditional antibiotic-based treatments and has significant implications for combating antimicrobial resistance.
A Johns Hopkins study shows that a higher dose of the antibiotic rifampin may be more effective in treating TB meningitis, potentially leading to improved patient outcomes. The research suggests that high doses of rifampin can kill bacteria faster while minimizing brain inflammation.
Researchers at Texas Biomedical Research Institute have found that adding an antibody to the widely-used TB vaccine significantly improves its long-term effectiveness. The combination of the vaccine and an IL-10 blocker allows for better control of TB infection in mice, with improved lung health and increased memory immune cells.
Analyses of ancient TB genomes from coastal Peru and inland Colombian Andes sites reveal a marine-associated strain of the pathogen that suggests a zoonosis from seals. The findings support a complex distribution network for TB on land, with trade networks potentially playing a key role in transporting the pathogen.
Researchers found that four-month treatment is as effective as six months in non-severe TB cases, allowing for savings on screening and training healthcare workers. The study's results led to a change in the World Health Organisation's global guidelines, recommending a shorter treatment course for children with non-severe TB.
A recent study found a high prevalence of HIV, tuberculosis, and malaria in the Gambela region of Ethiopia, highlighting the need for targeted health services. The research suggests that addressing these diseases at a local level could be more effective than a nationwide response.
A study led by A*STAR's Genome Institute of Singapore has identified the gene KCNJ15 as a key player in helping the immune system fight tuberculosis. The research found that TB patients have altered acetylation levels at thousands of DNA regions, which helps to reduce the ability of bacteria to reproduce inside cells.
Researchers found that starting combined antiretroviral therapy against simian immunodeficiency virus two weeks after infection significantly reduced chronic immune activation, SIV replication, and latent TB reactivation. This study contributes to the growing evidence on the complex interaction between HIV and tuberculosis.
Researchers identified 40 peptide pairs with potential cross-reactivity between BCG vaccination and SARS-CoV-2, offering a new strategy to complement existing COVID-19 vaccines. These peptides can induce T cell responses and INF-γ production, providing long-lasting immunity against viral infections.
Researchers at Weill Cornell Medicine discovered that deleting the EtfD Mtb enzyme renders Mycobacterium tuberculosis unable to sustain an infection in mice. The enzyme plays a critical role in fatty acid breakdown, making it an attractive target for TB treatment.
Researchers identified 'pre-resistance' signs in bacteria, predicting future resistance to antibiotics. This discovery allows doctors to select the best treatments for bacterial infections and paves the way for personalized genomic therapy.
Researchers at La Jolla Institute for Immunology identified Th1* cells as a key marker in the body's immune signature following BCG vaccination. The study found that these cells respond well to the vaccine and can help fight the Mycobacterium tuberculosis bacterium that causes TB.
Researchers analyzed TB and COVID-19 patients in California, finding shared sociodemographic characteristics and medical risk factors. The study highlights the importance of addressing these factors to improve health outcomes for both conditions.
Researchers at the University of Alabama at Birmingham discovered the mechanism of secretion and trafficking of Mycobacterium tuberculosis' toxin TNT, which kills over 1 million people annually. The ESX-4 type VII secretion system plays a crucial role in transporting TNT across cell membranes.
A study led by New York University researchers found that the FDA-approved hepatitis C treatment telaprevir can increase bacterial sensitivity to antibiotics and reduce antibiotic resistance. The antiviral blocks the function of essential proteins in bacteria, revealing an opportunity to repurpose the drug to use alongside antibiotics.
Infants who contract cytomegalovirus (CMV) before age 12 months are at a significantly higher risk of developing TB later in their childhood. The study found that babies infected with CMV were more than three times more likely to develop TB after age 1 than children who had not become infected with CMV.
Researchers at Trinity College Dublin have discovered that lactate can influence cells in the lung environment to support immune defenses against infection while limiting collateral damage. Lactate may hold therapeutic potential as a host-directed therapy for diseases like TB and COVID-19, which cause destruction of pulmonary tissue.
A study published in The Lancet Global Health found that nearly one-fifth of young people with tuberculosis (10-24 years old) in Brazil experienced adverse treatment outcomes. Factors associated with these outcomes included poverty, HIV, homelessness, and drug use, highlighting the need for greater attention to this age group in tuberc...
Researchers discovered a DNA modification system that coordinates bacterial replication in TB. The DarT/DarG system can be targeted by new antibiotics, offering hope for treating the deadly disease.
A new TB prevention regimen for HIV-positive individuals has shown promising results, with 90.4% completing the three-month course compared to 50.5% of those on a six-month daily treatment. The study suggests that this shorter approach is as safe and effective as the standard treatment.
A randomized trial found that a shorter course of rifapentine-isoniazid therapy resulted in significantly higher treatment completion rates compared to a longer daily course. The findings suggest that this regimens can be more effective for preventing tuberculosis disease in individuals with HIV, particularly in high-transmission areas.
Researchers at Purdue University and Houston Methodist have developed a novel TB vaccine formulation that enhances T cell responses to combat tuberculosis. The new vaccine uses autophagy-mediated antigen presentation, showing promising results in improving immune response.
Scientists at Rockefeller University have discovered that essential gene targets in TB bacteria can be ranked by their degree of vulnerability to antibiotics. The study found that ideal targets are highly susceptible to inhibition, while invulnerable genes can withstand nearly total inhibition. This research provides new insights into ...
Researchers at the University of Maryland discovered a gene in tuberculosis that inhibits the inflammasome, a signaling system that helps defend against pathogens. The finding may lead to effective gene-based treatments or preventative therapies for tuberculosis.
Researchers created a 3D view of diseased lung tissue using microCT to reveal that TB granulomas are complex and branched, with unique connections to airways. This has significant implications for treatment, including the potential for aerosolized drug delivery to reduce treatment times.
The UNITE4TB partnership aims to develop new and highly active TB treatment regimens for drug-resistant and -sensitive TB. The consortium will accelerate the clinical evaluation of combinations of existing and novel drugs through advanced trial designs and AI-powered analysis.
The UNITE4TB partnership aims to develop new and highly active TB treatment regimens for drug-resistant and -sensitive TB. The 7-year project will utilize advanced clinical trials networks, adaptive trial designs, and machine learning techniques to accelerate the development of better treatment solutions.
Researchers have discovered a new approach to treating tuberculosis by boosting the body's immune system and targeting cell death pathways. The study found that using preclinical models, infected cells can be killed by drugs called IAP inhibitors, significantly reducing disease severity.
A study published at ECCMID 2021 found that individuals with depression and schizophrenia have a higher incidence of TB. The research suggests that mental health may play a causal role in increasing TB risk, particularly through its effect on the immune system.
Scientists from Hackensack Meridian Center for Discovery and Innovation have uncovered the mechanism of action of a novel anti-tuberculosis drug, triaza-coumarin, which is effective in inhibiting TB disease from within by boosting its on-target activity by two orders of magnitude.
The study of Mycobacterium tuberculosis's ESX-5 secretion system reveals a complex molecular machinery that enables the bacterium to infect human cells. The structure of this system provides potential drug targets and new insights into vaccine development.
A Phase 2 trial showed that combining doxycycline with TB treatment reduces lung cavity size and increases markers of recovery in pulmonary TB patients. This discovery has promise for preventing long-term complications and improving outcomes for those affected by the disease.
A comprehensive health-screening program in rural northern KwaZulu-Natal, South Africa, has identified a high burden of undiagnosed or poorly controlled non-communicable diseases. The study found that four out of five women over the age of 30 were living with chronic health conditions, highlighting the need for urgent interventions.
A new study validates the Xpert Ultra molecular test as a frontline tool in routine conditions, showing improved sensitivity over its predecessor. The test detects tuberculosis cases with lower bacterial burdens and can identify asymptomatic cases in early stages of the disease.
Researchers discovered a stem cell-mediated defense mechanism that reactivates dormant tuberculosis in mice infected with SARS-CoV-2, suggesting potential for new vaccines and avoiding global TB pandemic. This discovery may help develop novel therapeutic approaches against COVID-19 and target antiviral activities.
Researchers have identified seven genes responsible for excessive inflammation and damage to the lungs in tuberculosis. A new drug treatment, doxycycline, has shown promise in reducing lung damage and accelerating recovery in patients with pulmonary TB.
Researchers have found a new four-month antibiotic regimen using rifapentine to be effective in treating TB, reducing the treatment duration by two months. The study showed that patients with HIV also cleared their TB just as well as those without HIV.
A recent study on TB outbreak in an Irish prison highlights the need for increased testing and improved care. The study found that 50% of staff may have developed latent TB as a result of occupational exposure, posing a risk of progression to active TB.
A multinational study validated a four-month multi-drug therapy regimen as effective as the standard six-month treatment for active tuberculosis, reducing treatment time by a third. The new regimen, which includes rifapentine and moxifloxacin, was safe and well-tolerated.
Researchers developed a new basis for comparing tuberculosis treatments using an rRNA synthesis ratio, enabling more intelligent drug design and acceleration of treatments. This tool has crucial implications for combatting the global TB epidemic by providing a durable cure.
The new test detects a specific protein (CFP-10) in children's blood samples with high sensitivity and accuracy, identifying TB cases with 100% accuracy. It can detect TB up to 60 weeks before diagnosis, offering early detection and potentially saving lives.
Scientists at the University of Surrey detail how they measure metabolite fluxes in Mycobacterium tuberculosis, crucial for understanding its survival and developing effective treatments. This breakthrough could accelerate progress towards eliminating tuberculosis globally.
A groundbreaking study has identified IL-17 cytokine as the primary culprit behind excessive lung inflammation in TB patients. By targeting this pathway, doctors may be able to reduce disease harm and speed up patient recovery.
Researchers developed a genetic material-based catalogue to predict antibiotic resistance in MDR-TB, enabling accelerated treatment development. The study found that 99% of predicted drug combinations were effective in traditional microbiological testing.
New research reveals fundamental differences in how baby and adult immune cells respond to TB, with a greater ability of adult cells to shift their energy profile after infection. The study highlights the importance of understanding how the immune system uses energy to develop better treatments for vulnerable populations.
Researchers identified Mycobacterium tuberculosis' use of rubredoxin B to survive in iron-deficient conditions, helping the bacterium evade the immune system. The study provides new insights into the development of drug resistance and potential targets for therapeutic agents.
Researchers at the University of Alabama at Birmingham have discovered a novel protein transport system in Mycobacterium tuberculosis, allowing the release of its toxin, tuberculosis necrotizing toxin (TNT), into human macrophages. The study reveals that two small Esx proteins form pores in membranes to facilitate TNT secretion.
The TB burden in Europe is decreasing, with a 19% overall decline from 2015-2019. However, drug resistance remains a major concern, and the COVID-19 pandemic may stall or cause setbacks in the fight against TB. Treatment outcomes are suboptimal, with only 77% of patients successfully completing treatment in 2019.
Researchers found that adding an iron binder to Bedaquiline treatment boosts its ability to combat TB bacteria. The study suggests a promising approach to improving patient outcomes and developing new treatments.
Researchers at Radboud University Medical Center have found that a higher dose of the anti-tuberculosis drug rifampicin is safe and effective. This could lead to a shorter treatment duration and less resistance, with potential benefits for global tuberculosis treatment.
A new report by Harvard Medical School researchers found that TB diagnoses in the US are often delayed, leading to a higher likelihood of infection transmission and disease progression. The study suggests that increased clinician awareness and education can help minimize these delays.
Researchers analyzed ancient human DNA to understand the impact of tuberculosis on European populations. The study found that a specific variant of the TYK2 gene was associated with an increased risk of becoming ill after infection with Mycobacterium tuberculosis.
Researchers analyzed 70,000 ancient skeletons to find declining rates of transmission for these chronic infectious diseases. The analysis suggests that pathogens may evolve to cause less harm to humans over time, leading to reduced transmission.
A MUSC researcher has been awarded a $9.9 million contract to test TB treatment interventions in areas with severe disease prevalence. The goal is to shorten treatment duration and improve patient adherence, particularly for individuals with latent TB infection.
Researchers have isolated monoclonal antibodies that effectively target and inhibit the growth of tuberculosis germs in laboratory mice. These biological antibiotics show promise as an alternative to traditional chemical antibiotics, offering a safer and more stable treatment option.